MDGL — Madrigal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $10.62bn
- $10.13bn
- $958.40m
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CBRE Group, Horizon Bancorp, Ulta Beauty
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Brief: Madrigal Receives European Commission Approval for Rezdiffra For Treatment of MASH With Moderate To Advanced Liver Fibrosis
U.S. STOCKS ON THE MOVE-Soho House, Cogent Communications, Beyond
U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx
Madrigal Pharma down; Novo's Wegovy gets FDA approval for liver disease
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Madrigal Pharmaceuticals Q2 EPS USD -1.9
Madrigal signs up to $2 billion deal to develop CSPC Pharma's GLP-1 drug (updated)
Brief: CSPC Pharmaceutical Enters Into Exclusive License Agreement For SYH2086 With Madrigal
Madrigal and CSPC Pharmaceutical sign up to $2 billion licensing deal
U.S. RESEARCH ROUNDUP-Bank of America, Goldman Sachs, Microsoft
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
EU medicines regulator grants conditional authorisation for Madrigal's liver disease drug (updated)
Brief: Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq listing rule
Brief: Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis
Madrigal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary